Given that ccRCC is characterized as a “metabolism-related disease,” particularly in terms of lipid metabolism, the unexplored HIF-2α/LPCAT1/ACLY pathway may present a promising therapeutic target for controlling this tumor. Here, ACLY is linked to nonpapillary renal cell carcinoma.